Healio

FDA approves inclisiran monotherapy for LDL lowering

Please provide your email address to receive an email when new articles are posted on . Inclisiran is now FDA approved as monotherapy for LDL reduction. The drug is no longer required to be used on ...
TCTMD

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

ATLANTA, GA—Using inclisiran (Leqvio; Novartis) as soon as possible in the care of patients with atherosclerotic cardiovascular disease (ASCVD) is associated with sustained lowering of LDL cholesterol ...
TCTMD

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Prolonged exposure to inclisiran (Leqvio; Novartis), the small-interfering RNA therapy (siRNA) that lowers LDL-cholesterol levels, is safe and well tolerated in a wide group of patients with ...
Nasdaq

FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year

With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1 Leqvio provides effective and sustained LDL-C ...
The American Journal of Managed Care

Inclisiran Significantly Lowers LDL-C in V-MONO Study

Twice-yearly inclisiran (Leqvio) monotherapy showed clinically meaningful and statistically significant LDL-C lowering in patients at low or moderate risk of atherosclerotic cardiovascular disease in ...
Seeking Alpha

US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease

EAST HANOVER, N.J., July 10, 2023 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran) to enable earlier use in ...
Seeking Alpha

Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use

Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C) 1 4 out of 5 atherosclerotic ...